Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Synchron

Biotech & Life Sciences · New York City, United States · Founded 2012

Synchron is a pioneering company in the medical technology sector, aiming to revolutionize healthcare by providing unprecedented access to brain data. Founded in 2012, Synchron focuses on developing brain-computer interface (BCI) technology that allows individuals to control digital devices using their thoughts. This technology is particularly transformative for patients with severe paralysis, offering them a new level of autonomy and social connection. The company's flagship product involves a minimally invasive endovascular procedure, akin to the placement of stents, which eliminates the need for open brain surgery. This procedure allows the BCI to be implanted safely and efficiently, making it accessible to a broader range of patients. Synchron primarily serves patients with neurological conditions that impair their ability to communicate or move. These clients benefit from the ability to control computers and other digital devices using their thoughts, significantly improving their quality of life. The company operates in the medical technology market, which is rapidly growing due to advancements in healthcare and increasing demand for innovative treatments. The business model of Synchron revolves around the development, clinical testing, and commercialization of its BCI technology. The company generates revenue through the sale of its medical devices and related services. Additionally, Synchron may engage in partnerships with healthcare providers and institutions to expand the reach and application of its technology. The leadership team at Synchron comprises global experts in neuroscience, vascular bionics, and medical technology, including CEO Tom Oxley and Founding Director Nick Opie. Their combined expertise drives the company's mission to empower patients and transform medicine. In summary, Synchron is at the forefront of medical innovation, offering groundbreaking solutions for patients with severe neurological impairments. By leveraging advanced BCI technology, the company is making significant strides in improving patient autonomy and social connectivity. Keywords: Brain-computer interface, minimally invasive, endovascular procedure, neurological conditions, patient autonomy, digital control, medical technology, healthcare innovation, paralysis treatment, brain data.

Valuation
$500M–1B
Latest valuation · 2025
Unlock exact value
Headcount
100–500
Current team size
Unlock exact value
Total funding Pre-IPO
$100–500M
Unlock exact value

Investors

32 investors on Synchron's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
National Institutes of Health
Series A 14 investors entered at this stage
Sigma Partners
NeuroTechnology Investors
DARPA
Khosla Ventures
Forepont Capital Partners
Subversive Capital
ID8 Investments
Thomas Reardon
General Advance
Shanda Group
Arani Bose
re.Mind Capital
METIS innovative
Wesley College
Series B+ 17 investors entered at this stage
Max Hodak
ARCH Venture Partners
Alumni Ventures
Reliance Industries
Moore Strategic Ventures
Gates Frontier
Greenoaks Capital Partners
Bezos Expeditions
University of Melbourne
Project X
Double Point Ventures
Qatar Investment Authority
Protocol Labs
K5 Global
T.Rx Capital
Australian National Reconstruction Fund
IQT Group

Global footprint

Where Synchron has talent and traffic

Workforce by country
5 countries with
team presence
🇺🇸 United States89.6%
🇦🇺 Australia6.5%
🇮🇪 Ireland1.3%
🇨🇦 Canada1.3%
🇬🇧 United Kingdom1.3%
5 countries shown

Talent graph

The shape of Synchron's talent

Dealroom maps Synchron's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

12 team members profilednamed & role-tagged by Dealroom
131 employeestotal headcount
5 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Synchron's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Synchron

An AI-synthesized read of the highest-engagement posts about Synchron on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Synchron on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.